These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21473814)

  • 41. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
    McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
    Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
    Driedger SM; Cooper E; Annable G; Brouwers M
    Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Presentation of economic evaluation results.
    Chaikledkaew U
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S72-80. PubMed ID: 24964702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Ethical Analysis of Coverage With Evidence Development.
    Carter D; Merlin T; Hunter D
    Value Health; 2019 Aug; 22(8):878-883. PubMed ID: 31426928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
    Fletcher C; Chuang-Stein C; Paget MA; Reid C; Hawkins N
    Pharm Stat; 2014; 13(4):265-74. PubMed ID: 24931490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
    Tarricone R; Torbica A; Ferré F; Drummond M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):707-18. PubMed ID: 25196848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using evidence to inform coverage decisions: the Washington State experience.
    Blackmore CC
    Acad Radiol; 2012 Sep; 19(9):1055-9. PubMed ID: 22877985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems.
    Main C; Moxham T; Wyatt JC; Kay J; Anderson R; Stein K
    Health Technol Assess; 2010 Oct; 14(48):1-227. PubMed ID: 21034668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
    Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN HEALTHCARE SYSTEM IN SLOVENIA.
    Prevolnik Rupel V
    Int J Technol Assess Health Care; 2017 Jan; 33(3):360-364. PubMed ID: 28434423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
    Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
    J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implementing managed entry agreements in practice: The Dutch reality check.
    Makady A; van Veelen A; de Boer A; Hillege H; Klungel OH; Goettsch W
    Health Policy; 2019 Mar; 123(3):267-274. PubMed ID: 30316540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KNOW ESSENTIALS: a tool for informed decisions in the absence of formal HTA systems.
    Mathew JL
    Int J Technol Assess Health Care; 2011 Apr; 27(2):139-50. PubMed ID: 21447262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coverage with evidence development for medical devices in Europe: Can practice meet theory?
    Drummond M; Federici C; Reckers-Droog V; Torbica A; Blankart CR; Ciani O; Kaló Z; Kovács S; Brouwer W
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):179-194. PubMed ID: 35220644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group.
    Hoffmann C; Graf von der Schulenburg JM
    Health Policy; 2000 Jul; 52(3):179-92. PubMed ID: 10862993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation.
    Grimm SE; Pouwels X; Ramaekers BLT; van Ravesteyn NT; Sankatsing VDV; Grutters J; Joore MA
    Value Health; 2021 Aug; 24(8):1126-1136. PubMed ID: 34372978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.